Search Results
Development of peptide-drug conjugates for the treatment of Chronic Myelomonocytic Leukaemia (CMML)
We are aiming to bring a new treatment option to patients with chronic myelomonocytic leukemia (CMML) by utilising CCL2-drug conjugates that specifically target and eliminate cancerous cells. Our leading conjugate shows potent and selective efficacy in killing CMML cells. The proposed work will help us understand how this drug works, which patients are most likely to benefit and how it can be combined with current treatments to achieve the greatest patient benefit.
Finding Support in Community: Walgreens and LLS Show Up for Blood Cancer Patients
We all need a helping hand sometimes.
Add on a cancer diagnosis and the everyday suddenly feels... different. In many ways, harder.
Cancer Won’t Stop Coach Marie
Thousands of runners will hit the streets of Chicago this weekend for the 2016 Chicago Marathon. Before they cross the start and finish lines, they will go through an intense training program to meet one of their most challenging goals: 26.2 miles.
As a coach for The Leukemia & Lymphoma Society’s Team In Training (TNT), Marie Jarrell of Chicago is the inspiring drumbeat for hundreds of Chicago marathon trainees every year, leading them down the path to fitness and providing them with inspiration along the way.
Rituximab
is FDA approved for the treatment of:
Interferon alfa-2a
Interferons are substances naturally produced by cells in the body to help fight infections and tumors. They may also be synthetic versions of these substances. Interferon alfa-2a is FDA approved to treat people who have hairy cell leukemia and Philadelphia chromosome positive chronic myeloid leukemia who are minimally pretreated (within 1 year of diagnosis). It may cause a temporary loss of hair. After treatment has ended, normal hair growth should return.
Ibrutinib
Ibrutinib has been FDA-approved to treat:
- Patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (SLL) with 17p deletion.
- Patients with Waldenström macroglobulinemia (WM).
- Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.
Epigenetic heterogeneity in age-related clonal hematopoiesis and acute myeloid leukemia
Our focus is to unravel how clonal hematopoiesis (CH) progresses to leukemia. We will investigate how epigenetic heterogeneity affects Tet2-mutant hematopoietic stem cells (HSCs) during aging. We plan to simultaneously trace HSC clonal identity and clonal history by genetic barcode and single-cell multi-omics and determine their epigenetic configurations adaptive in the aged, inflammatory bone marrow. The long-term goal is to create innovative therapeutics to mitigate CH and prolong health span.Stopping Gleevec to Start a Family
Erin Zammett Ruddy is a magazine journalist and blogger who was diagnosed with chronic myeloid leukemia at age 23. Today, she is a 40-year-old mother of three.
On January 30 I turned 40. The big 4-0! My grandma Adele and I shared a birthday, and she’d be aghast if she knew I was telling all of you my real age right now. Grandma Del was a Radio City Rockette and very glamorous—and she never turned a day over 29, despite living to 85 (sorry, Grandma). But I am damn proud of being 40, newly-formed wrinkles and all.
#ASH18: Update on Immunotherapy
Immunotherapy – harnessing the body’s immune system to fight disease – is rapidly becoming a mainstay of cancer treatment. The increasing interest in this field was clear at yesterday’s standing-room only symposium hosted by The Leukemia & Lymphoma Society in advance of the 60th ASH (American Society of Hematology) Meeting which officially kicks off today here in San Diego. Over the next few days more than 30,000 researchers and others connected to the blood cancers and other blood malignancies will gather to hear the latest data from clinical trials.
Blood Cancer Survivors Find Special Meaning and Connection as Employee Champions of LLS Light the Night Events
The Leukemia & Lymphoma Society (LLS) is proud of our continuing partnership with Gilead and Kite Oncology as the National Presenting Sponsor of Celebration and Community at Light The Night events across the U.S. helping bring people together and raise critical funds to support patients and their families.
Remembering Robbie
On Friday, October 20, 1944, Robert “Robbie” Roesler de Villiers was only 16 years old when he died from leukemia. Robbie’s parents, Rudolph and Antoinette, were stricken with grief and frustrated by the lack of effective treatments for what was then considered a hopeless disease. In his memory, the family started a foundation in 1949.
Dasatinib
Dasatinib is FDA approved to treat
Midostaurin
Rydapt is FDA approved for the treatment of adult patients with:
- Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.
Limitations of Use:
RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML. - Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
Progress on AML but More Work to Do
A Q&A with Amy Burd, PhD, LLS Vice President of Research Strategy
Today is AML World Awareness Day, a day to acknowledge the struggle to tackle one of the most challenging blood cancers, while shining a light on advances in the prevention, management and treatment of acute myeloid leukemia (AML).